TORL Biotherapeutics LLC announced that it will receive $158,300,000 in funding on April 4, 2024. The company will issue membership units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.1 USD | -0.59% | -3.77% | -15.49% |
02:34pm | Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab | MT |
01:32pm | Bristol Myers: deadline set for subcutaneous Opdivo | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.49% | 87.9B | |
+34.35% | 705B | |
+31.04% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.13% | 238B | |
-3.76% | 210B | |
+10.12% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it expects to receive $158.3 million in funding